尊龙凯时

    At the end of 2021, SynRx Therapeutics completed a PRE-A round of financing, which was led by Haibang Fenghua Venture Capital  with a number of well-known investment institutions including Westlake Innovation Capital in participation.

     This round of financing is mainly utilized for the establishment of the company's branch in Shanghai, the construction of laboratories , the product pipeline development for each project, and the introduction of high-educated domestic and foreign talents.

    Founded in August 2021, SynRx Therapeutics is an innovative R&D company focusing on the development of novel anti-tumor drugs using synthetic lethality approaches. We are currently exploring several first-in-class, anti-tumor compounds, and preclinical studies are in progress .